Navigation Links
CardioGenics Requests Stockholders to Participate in Stockholder Questionnaires
Date:3/8/2011

MISSISSAUGA, Ontario, March 8, 2011 /PRNewswire/ -- CardioGenics Holdings Inc. (OTC Bulletin Board: CGNH) announced today that it is making available to its common stockholders and Series 2 Class B common stockholders a "Stockholder Questionnaire," which the Company hopes will assist it in obtaining an accurate share count of the Company's shares currently held in "street name" through brokers, banks or other nominees.

If you have not received the Stockholder Questionnaires via mail, you can download copies of the questionnaires from the "Investor Relations" section of the Company's website (www.cardiogenics.com). We urge all stockholders to take the time to complete and return the applicable questionnaire to the Company as soon as possible. The questionnaires contain the mailing address, fax number and e-mail address, which can be used by stockholders for returning their completed questionnaires.

Any inquiries regarding the questionnaires can be directed to Creative Capital and Trading, Inc., which is assisting the Company in this matter:

Creative Capital and Trading, Inc.

Attention: Tony Forte – Tel: 732-751-1947 or

Jeff Goss – Tel: 732-556-6924

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's principal offices are located in Mississauga, Ontario, Canada. For more information please visit www.cardiogenics.com.

Safe Harbor Statement - Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995 and may contain forward-looking statements, with words such as "anticipate, "believe," "expect," "future," "may," "will," "should," "plan," "projected," "intend," and similar expressions to identify forward-looking statements. These statements are based on the Company's beliefs and the assumptions it made using information currently available to it. Because these statements reflect the Company's current views concerning future events, these statements involve risks, uncertainties and assumptions. The actual results could differ materially from the results discussed in the forward-looking statements. In any event, undue reliance should not be placed on any forward-looking statements, which apply only as of the date of this press release. Accordingly, reference should be made to the Company's periodic filings with the Securities and Exchange Commission.


'/>"/>
SOURCE CardioGenics Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CardioGenics Granted Patent for Core Technology of its QL Care™ Analyzer
2. CardioGenics to File for 510K Clearance With the United States Food and Drug Administration by Q4 2011
3. CardioGenics to Continue Commercialization of its Magnetic Beads with Merck Chimie SAS
4. CardioGenics Raises $1.9 Million in Private Placement
5. CardioGenics Featured on Cover of Medical Device & Diagnostic Industry Magazine
6. Zacks Rates CardioGenics Outperform With Six-Month Target of $1.22
7. CardioGenics Featured on Canadas Business News Network
8. CardioGenics Holdings Inc. Receives New Ticker Symbol
9. CardioGenics Selects Clinical Test Sites for Its High Speed Portable Blood Analyzer
10. New Corporate Profile Posted On CardioGenics Website
11. CardioGenics Announces Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
(Date:2/23/2017)... -- Cogentix Medical, Inc. (NASDAQ: CGNT), a medical device company ... the urology market, will release financial results for the ... before the market open on Thursday, March 9, 2017. ... call and webcast to discuss its financial results the ... a.m. Eastern Time (10:00 a.m. Central Time). Darin ...
(Date:2/23/2017)... 23, 2017 Research and Markets has announced ... Strategies - 2016" report to their offering. ... The latest research Oesophageal Cancer ... and benchmarks in the global Oesophageal Cancer market. The ... are the key drugs marketed for Oesophageal Cancer and their clinical ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica ... in thought leadership , media relations, social media, content marketing and SEO, ... be powered through Act-On, an intuitive marketing automation platform. , Rosica will now ...
(Date:2/23/2017)... ... 23, 2017 , ... On February 22, 2017 the U.S. ... to withdraw previous guidance issued by the Obama Administration requiring schools to treat ... 2016 by the Obama Administration came in response to a growing number of ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... EBSCO Information Services ... Institute for Health and Care Excellence (NICE) framework. The agreement allows purchasers ... (NHS) to search, order and purchase medical and healthcare-related content through GOBI ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):